Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $8,586 | 1 | 46.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,000 | 1 | 32.8% |
| Travel and Lodging | $2,962 | 11 | 16.2% |
| Food and Beverage | $726.43 | 15 | 4.0% |
| Education | $41.78 | 2 | 0.2% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Actelion Pharmaceuticals, Ltd | $9,461 | 10 | $0 (2020) |
| United Therapeutics Corporation | $6,915 | 9 | $0 (2017) |
| Actelion Pharmaceuticals US, Inc. | $1,899 | 9 | $0 (2017) |
| Bayer HealthCare Pharmaceuticals Inc. | $41.78 | 2 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2020 | $875.04 | 9 | Actelion Pharmaceuticals, Ltd ($875.04) |
| 2019 | $8,586 | 1 | Actelion Pharmaceuticals, Ltd ($8,586) |
| 2017 | $8,856 | 20 | United Therapeutics Corporation ($6,915) |
All Payment Transactions
30 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/12/2020 | Actelion Pharmaceuticals, Ltd | — | Travel and Lodging | In-kind items and services | $39.10 | General |
| 02/12/2020 | Actelion Pharmaceuticals, Ltd | — | Food and Beverage | In-kind items and services | $38.95 | General |
| 02/12/2020 | Actelion Pharmaceuticals, Ltd | — | Food and Beverage | In-kind items and services | $29.48 | General |
| 02/12/2020 | Actelion Pharmaceuticals, Ltd | — | Food and Beverage | In-kind items and services | $14.96 | General |
| 02/12/2020 | Actelion Pharmaceuticals, Ltd | — | Food and Beverage | In-kind items and services | $14.60 | General |
| 02/11/2020 | Actelion Pharmaceuticals, Ltd | — | Travel and Lodging | In-kind items and services | $334.21 | General |
| 02/11/2020 | Actelion Pharmaceuticals, Ltd | — | Travel and Lodging | In-kind items and services | $236.17 | General |
| 02/11/2020 | Actelion Pharmaceuticals, Ltd | — | Food and Beverage | In-kind items and services | $94.08 | General |
| 02/11/2020 | Actelion Pharmaceuticals, Ltd | — | Travel and Lodging | In-kind items and services | $73.49 | General |
| 05/13/2019 | Actelion Pharmaceuticals, Ltd | — | — | Cash or cash equivalent | $8,586.08 | Research |
| Study: TRACE | ||||||
| 12/02/2017 | Actelion Pharmaceuticals US, Inc. | — | Travel and Lodging | Cash or cash equivalent | $922.70 | General |
| 12/02/2017 | Actelion Pharmaceuticals US, Inc. | — | Food and Beverage | In-kind items and services | $96.91 | General |
| 12/02/2017 | Actelion Pharmaceuticals US, Inc. | — | Food and Beverage | In-kind items and services | $75.38 | General |
| 12/02/2017 | Actelion Pharmaceuticals US, Inc. | — | Food and Beverage | In-kind items and services | $43.07 | General |
| 12/01/2017 | Actelion Pharmaceuticals US, Inc. | — | Travel and Lodging | Cash or cash equivalent | $144.74 | General |
| 12/01/2017 | Actelion Pharmaceuticals US, Inc. | — | Food and Beverage | In-kind items and services | $84.98 | General |
| 12/01/2017 | Actelion Pharmaceuticals US, Inc. | — | Food and Beverage | In-kind items and services | $66.09 | General |
| 12/01/2017 | Actelion Pharmaceuticals US, Inc. | — | Food and Beverage | In-kind items and services | $37.77 | General |
| 11/30/2017 | Actelion Pharmaceuticals US, Inc. | — | Travel and Lodging | Cash or cash equivalent | $427.44 | General |
| 06/02/2017 | United Therapeutics Corporation | TYVASO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,000.00 | General |
| Category: PAH | ||||||
| 06/02/2017 | United Therapeutics Corporation | TYVASO (Drug) | Travel and Lodging | Cash or cash equivalent | $283.02 | General |
| Category: PAH | ||||||
| 06/02/2017 | United Therapeutics Corporation | TYVASO (Drug) | Travel and Lodging | Cash or cash equivalent | $283.02 | General |
| Category: PAH | ||||||
| 06/02/2017 | United Therapeutics Corporation | TYVASO (Drug) | Travel and Lodging | Cash or cash equivalent | $182.45 | General |
| Category: PAH | ||||||
| 06/02/2017 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $48.21 | General |
| Category: PAH | ||||||
| 06/02/2017 | United Therapeutics Corporation | TYVASO (Drug) | Travel and Lodging | Cash or cash equivalent | $36.00 | General |
| Category: PAH | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| TRACE | Actelion Pharmaceuticals, Ltd | $8,586 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 5 | 89 | 141 | $26,150 | $7,838 |
| 2020 | 7 | 235 | 370 | $73,369 | $23,977 |
All Medicare Procedures & Services
12 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 24 | 57 | $13,038 | $4,441 | 34.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 17 | 17 | $4,335 | $966.64 | 22.3% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 18 | 33 | $3,080 | $930.96 | 30.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 11 | 15 | $2,657 | $820.00 | 30.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 19 | 19 | $3,040 | $679.40 | 22.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 63 | 107 | $24,390 | $8,384 | 34.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 34 | 34 | $17,850 | $5,332 | 29.9% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 38 | 113 | $9,073 | $3,403 | 37.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 46 | 61 | $9,304 | $3,380 | 36.3% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 15 | 15 | $4,452 | $1,623 | 36.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 20 | 20 | $5,100 | $1,062 | 20.8% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 19 | 20 | $3,200 | $792.80 | 24.8% |
About Dr. Austin Thompson, MD
Dr. Austin Thompson, MD is a Pulmonary Disease healthcare provider based in Omaha, Nebraska. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1588614200.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Austin Thompson, MD has received a total of $18,317 in payments from pharmaceutical and medical device companies, with $875.04 received in 2020. These payments were reported across 30 transactions from 4 companies. The most common payment nature is "" ($8,586).
As a Medicare-enrolled provider, Thompson has provided services to 324 Medicare beneficiaries, totaling 511 services with total Medicare billing of $31,815. Data is available for 2 years (2020–2021), covering 12 distinct procedure/service records.
Practice Information
- Specialty Pulmonary Disease
- Location Omaha, NE
- Active Since 05/11/2006
- Last Updated 06/23/2011
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1588614200
Products in Payments
- TYVASO (Drug) $6,915
- Adempas (Drug) $41.78
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Omaha
Dr. Douglas Moore, M.d, M.D
Pulmonary Disease — Payments: $44,617
Stephen Rennard, Md, MD
Pulmonary Disease — Payments: $32,530
Patrick Meyers, M.d, M.D
Pulmonary Disease — Payments: $12,153
Lee Morrow, M.d, M.D
Pulmonary Disease — Payments: $10,157
Palvannanathan Ganesan, M.d, M.D
Pulmonary Disease — Payments: $8,217
Rosina Schiff, Do, DO
Pulmonary Disease — Payments: $5,578